Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 2/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 4/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104742 | 0.88 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1NR1I2CACNA1B | |
| SCHEMBL30430483 | 0.88 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1NR1I2CACNA1B | |
| SCHEMBL26103351 | 0.86 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1POLBFASN | |
| SCHEMBL26103330 | 0.83 | RORC (0.47) | L3MBTL3L3MBTL1MBTD1POLBFASN | |
| SCHEMBL26100203 | 0.80 | KDM1A (0.43) | L3MBTL3L3MBTL1MBTD1POLBFASN | |
| SCHEMBL30430028 | 0.80 | MBTD1 (0.42) | L3MBTL3L3MBTL1MBTD1NR1I2CACNA1B | |
| SCHEMBL26100540 | 0.80 | MBTD1 (0.42) | L3MBTL3L3MBTL1MBTD1NR1I2CACNA1B | |
| SCHEMBL23981996 | 0.77 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL26102750 | 0.77 | USP2 (0.39) | L3MBTL3L3MBTL1MBTD1FASN | |
| SCHEMBL30396674 | 0.76 | SLC6A9 (0.40) | L3MBTL3L3MBTL1MBTD1FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | F11 4525/4885L3MBTL3 3798/4885L3MBTL1 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.